PALI$1.23+9.37%
Palisade Bio, Inc.
Sector: Biological Products, (No Diagnostic Substances)Industry: BiotechnologyCountry: USExchange: Nasdaq
Mkt Cap:$217.65M
Float & O/S:
Inst Own:
DilutionScan read 49 of PALISADE BIO, INC.'s SEC filings and found 12 warrant series, 1 convertible, 6 shelf registrations, 3 S-1 registrations and 3 completed offerings on file for PALI. The latest dilution event on file is a registration statement on May 21, 2026. Analysis updated Oct 31, 2026.
Signal8 Summary
PALI
Pre-revenue biotech with massive dilution
Snapshot
Palisade Bio is a pre-revenue clinical-stage biotech developing treatments for gastrointestinal conditions. The company has no sales and reported a net loss of $16.8M in FY 2025, but its balance sheet is unusually strong for this stage.
What's Happening Right Now
- : Palisade Bio added biopharmaceutical veterans Robert Baltera and Jordan Zwick to its Board of Directors.
- : The company filed a shelf registration statement allowing it to offer up to $300 million of securities in the future.
- : Palisade Bio reported Q1 2026 financial results with a net loss of $0.05 per share and noted it is on track to start a Phase 2 ulcerative colitis trial in Q3 2026.
- : The company reported positive Phase 1b data for PALI-2108 in fibrostenotic Crohn's disease, showing endoscopic improvement and no serious adverse events.
